- Home
- CHRS vs SDST Comparison
CHRS vs SDST Comparison
Compare CHRS & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SDST
- Stock Information
- Founded
- CHRS 2010
- SDST 2022
- Country
- CHRS United States
- SDST United States
- Employees
- CHRS N/A
- SDST N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SDST Blank Checks
- Sector
- CHRS Health Care
- SDST Finance
- Exchange
- CHRS Nasdaq
- SDST Nasdaq
- Market Cap
- CHRS 84.2M
- SDST 37.0M
- IPO Year
- CHRS 2014
- SDST N/A
- Fundamental
- Price
- CHRS $0.85
- SDST $0.42
- Analyst Decision
- CHRS Buy
- SDST Buy
- Analyst Count
- CHRS 3
- SDST 2
- Target Price
- CHRS $4.68
- SDST $1.70
- AVG Volume (30 Days)
- CHRS 1.3M
- SDST 26.4M
- Earning Date
- CHRS 08-07-2025
- SDST 08-15-2025
- Dividend Yield
- CHRS N/A
- SDST N/A
- EPS Growth
- CHRS N/A
- SDST N/A
- EPS
- CHRS N/A
- SDST N/A
- Revenue
- CHRS $272,251,000.00
- SDST N/A
- Revenue This Year
- CHRS N/A
- SDST $3,681.67
- Revenue Next Year
- CHRS $99.43
- SDST N/A
- P/E Ratio
- CHRS N/A
- SDST N/A
- Revenue Growth
- CHRS 19.87
- SDST N/A
- 52 Week Low
- CHRS $0.66
- SDST $0.14
- 52 Week High
- CHRS $2.43
- SDST $28.38
- Technical
- Relative Strength Index (RSI)
- CHRS 53.52
- SDST N/A
- Support Level
- CHRS $0.73
- SDST N/A
- Resistance Level
- CHRS $0.96
- SDST N/A
- Average True Range (ATR)
- CHRS 0.05
- SDST 0.00
- MACD
- CHRS 0.02
- SDST 0.00
- Stochastic Oscillator
- CHRS 53.92
- SDST 0.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).